Report Detail
Global (United States, European Union and China) Myasthenia Gravis Drugs Market Research Report 2019-2025
- RnM3701655 |
- 27 August, 2019 |
- Global |
- 124 Pages |
- QYResearch |
- Pharma & Healthcare
Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.
In 2019, the market size of Myasthenia Gravis Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Myasthenia Gravis Drugs.
This report studies the global market size of Myasthenia Gravis Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Myasthenia Gravis Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Flamel Technologies
Roche
Grifols
Pfizer
Shire
Novartis
Valeant
Alexion
Catalyst
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Market Segment by Product Type
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins
Market Segment by Application
Hospitals
Clinics
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Myasthenia Gravis Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Myasthenia Gravis Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Myasthenia Gravis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Anticholinesterases
- 1.3.3 Immunosuppressants
- 1.3.4 Intravenous Immune Globulins
- 1.4 Market Segment by Application
- 1.4.1 Global Myasthenia Gravis Drugs Market Share by Application (2019-2025)
- 1.4.2 Hospitals
- 1.4.3 Clinics
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Myasthenia Gravis Drugs Market Size
- 2.1.1 Global Myasthenia Gravis Drugs Revenue 2014-2025
- 2.1.2 Global Myasthenia Gravis Drugs Sales 2014-2025
- 2.2 Myasthenia Gravis Drugs Growth Rate by Regions
- 2.2.1 Global Myasthenia Gravis Drugs Sales by Regions 2014-2019
- 2.2.2 Global Myasthenia Gravis Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Myasthenia Gravis Drugs Sales by Manufacturers
- 3.1.1 Myasthenia Gravis Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Myasthenia Gravis Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Myasthenia Gravis Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Myasthenia Gravis Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Myasthenia Gravis Drugs Price by Manufacturers
- 3.4 Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
- 3.6 Key Manufacturers Myasthenia Gravis Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Anticholinesterases Sales and Revenue (2014-2019)
- 4.1.2 Immunosuppressants Sales and Revenue (2014-2019)
- 4.1.3 Intravenous Immune Globulins Sales and Revenue (2014-2019)
- 4.2 Global Myasthenia Gravis Drugs Sales Market Share by Type
- 4.3 Global Myasthenia Gravis Drugs Revenue Market Share by Type
- 4.4 Myasthenia Gravis Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Myasthenia Gravis Drugs Sales by Application
6 United States
- 6.1 United States Myasthenia Gravis Drugs Breakdown Data by Company
- 6.2 United States Myasthenia Gravis Drugs Breakdown Data by Type
- 6.3 United States Myasthenia Gravis Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Myasthenia Gravis Drugs Breakdown Data by Company
- 7.2 European Union Myasthenia Gravis Drugs Breakdown Data by Type
- 7.3 European Union Myasthenia Gravis Drugs Breakdown Data by Application
8 China
- 8.1 China Myasthenia Gravis Drugs Breakdown Data by Company
- 8.2 China Myasthenia Gravis Drugs Breakdown Data by Type
- 8.3 China Myasthenia Gravis Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Myasthenia Gravis Drugs Breakdown Data by Company
- 9.2 Rest of World Myasthenia Gravis Drugs Breakdown Data by Type
- 9.3 Rest of World Myasthenia Gravis Drugs Breakdown Data by Application
- 9.4 Rest of World Myasthenia Gravis Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Myasthenia Gravis Drugs Sales by Countries
- 9.4.2 Rest of World Myasthenia Gravis Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Flamel Technologies
- 10.1.1 Flamel Technologies Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.1.4 Myasthenia Gravis Drugs Product Introduction
- 10.1.5 Flamel Technologies Recent Development
- 10.2 Roche
- 10.2.1 Roche Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.2.4 Myasthenia Gravis Drugs Product Introduction
- 10.2.5 Roche Recent Development
- 10.3 Grifols
- 10.3.1 Grifols Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.3.4 Myasthenia Gravis Drugs Product Introduction
- 10.3.5 Grifols Recent Development
- 10.4 Pfizer
- 10.4.1 Pfizer Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.4.4 Myasthenia Gravis Drugs Product Introduction
- 10.4.5 Pfizer Recent Development
- 10.5 Shire
- 10.5.1 Shire Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.5.4 Myasthenia Gravis Drugs Product Introduction
- 10.5.5 Shire Recent Development
- 10.6 Novartis
- 10.6.1 Novartis Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.6.4 Myasthenia Gravis Drugs Product Introduction
- 10.6.5 Novartis Recent Development
- 10.7 Valeant
- 10.7.1 Valeant Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.7.4 Myasthenia Gravis Drugs Product Introduction
- 10.7.5 Valeant Recent Development
- 10.8 Alexion
- 10.8.1 Alexion Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.8.4 Myasthenia Gravis Drugs Product Introduction
- 10.8.5 Alexion Recent Development
- 10.9 Catalyst
- 10.9.1 Catalyst Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.9.4 Myasthenia Gravis Drugs Product Introduction
- 10.9.5 Catalyst Recent Development
- 10.10 CSL
- 10.10.1 CSL Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Myasthenia Gravis Drugs
- 10.10.4 Myasthenia Gravis Drugs Product Introduction
- 10.10.5 CSL Recent Development
- 10.11 Curavac
- 10.12 Cytokinetics
- 10.13 Galencia
- 10.14 GlaxoSmithKline
- 10.15 Lupin Pharmaceuticals
- 10.16 Mitsubishi Tanabe Pharma
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Myasthenia Gravis Drugs Sales Channels
- 11.2.2 Myasthenia Gravis Drugs Distributors
- 11.3 Myasthenia Gravis Drugs Customers
12 Market Forecast
- 12.1 Global Myasthenia Gravis Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Myasthenia Gravis Drugs Sales Forecast by Type
- 12.3 Global Myasthenia Gravis Drugs Sales Forecast by Application
- 12.4 Myasthenia Gravis Drugs Forecast by Regions
- 12.4.1 Global Myasthenia Gravis Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Myasthenia Gravis Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Myasthenia Gravis Drugs. Industry analysis & Market Report on Myasthenia Gravis Drugs is a syndicated market report, published as Global (United States, European Union and China) Myasthenia Gravis Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Myasthenia Gravis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
